百令片治疗慢性肾小球肾炎的疗效及对免疫功能的影响
|
摘要
目的:主要探究百令片治疗慢性肾小球肾炎的疗效及对免疫功能的影响。方法:选择2014年1月-2016年1月在我院门诊或住院部明确诊断为慢性肾小球肾炎患者97例,按照随机数字法将患者分为治疗组(n=47)和对照组(n=50),对照组在常规治疗的基础上予厄贝沙坦治疗,治疗组在对照组的基础上予百令片治疗。所有患者均随访18个月。比较两组治疗后的中医疗效、24h尿蛋白定量、肌酐、e GFR及免疫功能。结果:经过18个月的治疗,治疗组中医疗效的总有效率为91.5%,对照组中医疗效的总有效率为74.0%,差异有统计学意义(P<0.05)。治疗组和对照组的24h尿蛋白定量均较治疗前有所下降(P<0.05),但两组治疗后的24h尿蛋白定量比较差异无统计学意义(P>0.05)。治疗组治疗后的血Cr为(87.2±23.7)μmol/L,显著低于对照组治疗后的(99.7±27.2)μmol/L(P<0.05)。治疗组治疗后的e GFR较治疗前升高(P<0.05),且高于对照组(P<0.05),而对照组治疗前后e GFR的差异无统计学意义(P>0.05)。治疗组治疗后的IL-6为(2.38±0.43)ng/L,显著低于对照组的(2.89±0.47)ng/L(P<0.05),两组治疗后的IL-8差异无统计学意义(P>0.05)。结论:百令片联合厄贝沙坦能有效减少慢性肾炎患者的蛋白尿,延缓患者肾功能的进展。
Objective: To assess efficacy and the influence of the Bailing tablets on immune function in patients with chronic glomerulonephritis. Methods: 97 patients were randomly divided into the treatment group(n=47) and control group(n=50). Both groups were given conventional treatments and irbesartan, and the treatment group was treated with the Bailing tablets more. Results: The efficiency of TCM was 91.5%, and higher than 74.0% in the control group(P<0.05). The 24-hour urine protein quantity was decreased in groups after treatment(P<0.05); there was no significant difference of 24-hour urine between two groups(P>0.05). The Cr in the treatment group was(87.2±23.7) μmol/L, and lower than(99.7±27.2) μmol/L in the control group. The e GFR in the treatment group was higher than before treatment and the contol group(P<0.05). The IL-6 in the treatment group was lower than the control group(P<0.05). There was no significant differences in IL-8 between groups(P>0.05). Conclusion: The Bailing tablets plus irbesartan on chronic glomerulonephritis can reduces the proteinuria, and delay the progress of kidney disease.
Objective: To assess efficacy and the influence of the Bailing tablets on immune function in patients with chronic glomerulonephritis. Methods: 97 patients were randomly divided into the treatment group(n=47) and control group(n=50). Both groups were given conventional treatments and irbesartan, and the treatment group was treated with the Bailing tablets more. Results: The efficiency of TCM was 91.5%, and higher than 74.0% in the control group(P<0.05). The 24-hour urine protein quantity was decreased in groups after treatment(P<0.05); there was no significant difference of 24-hour urine between two groups(P>0.05). The Cr in the treatment group was(87.2±23.7) μmol/L, and lower than(99.7±27.2) μmol/L in the control group. The e GFR in the treatment group was higher than before treatment and the contol group(P<0.05). The IL-6 in the treatment group was lower than the control group(P<0.05). There was no significant differences in IL-8 between groups(P>0.05). Conclusion: The Bailing tablets plus irbesartan on chronic glomerulonephritis can reduces the proteinuria, and delay the progress of kidney disease.
引文
[1]Wang S,Chen R,Liu Q,et al.Prevalence,awareness and treatment of chronic kidney disease among middle-aged and elderly:The China Health and Retirement Longitudinal Study[J].Nephrology,2015,20(7):474-484.
[2]Zhang L,Wang F,Wang L,et al.Prevalence of chronic kidney disease in China:a cross-sectional survey[J].Lancet,2012,379(9818):815-822.
[3]林基伟,邹川,刘旭生.基于数据挖掘方法总结黄春林名老中医治疗慢性肾炎的用药经验[J].世界科学技术-中医药现代化,2015,17(2):382-388.
[4]李艳.国医大师李济仁治疗慢性肾炎蛋白尿经验[J].中华中医药杂志,2010,25(1):83-86.
[5]谢永祥,谢丽萍,蓝芳,等.广西地区慢性肾炎中医证型演变规律以及与尿蛋白、肾功能的相关性研究[J].现代中西医结合杂志,2014,23(16):1715-1717.
[6]刘丰喆,贺斐,何立群,等.慢性肾炎肾性血尿的中医研究近况[J].中国中西医结合肾病杂志,2015,16(5):453-454.
[7]刘宝厚,许筠.慢性肾小球肾炎的诊断、辨证分型及疗效评定(试行方案)[J].上海中医药杂志,2006,40(6):8-9.
[8]王立新,蔡佑青,莫业南,等.三芪颗粒治疗慢性肾炎的临床研究[J].广州中医药大学学报,2017,34(3):321-325.
[9]冯婷婷,郑启刚,王珍.余秉治治疗慢性肾小球肾炎经验[J].河南中医,2017,37(4):587-589.
[10]张玥.益肾化湿颗粒联合缬沙坦治疗慢性肾小球肾炎的临床研究[J].世界中医药,2017,12(1):68-70.
[11]李名波,孙智梅,任卓琴,等.氯沙坦钾片联合肾炎康复片治疗慢性肾小球肾炎蛋白尿的疗效观察[J].中国医院用药评价与分析,2017,17(1):75-76.
[12]陈成,王亿平.王亿平教授治疗慢性肾小球肾炎经验总结[J].陕西中医药大学学报,2017,40(1):27-29.
[13]胡贤达,黄雪,王彪,等.冬虫夏草抗肿瘤及免疫调节作用的研究进展[J].药物评价研究,2015,38(4):448-452.
[14]王林萍,余意,冯成强.冬虫夏草活性成分及药理作用研究进展[J].中国中医药信息杂志,2014,21(7):132-136.
[15]郝丽,潘梦舒,郑云,等.冬虫夏草及雷公藤多甙对糖尿病肾病大鼠足细胞影响的实验研究[J].中国中西医结合杂志,2012,32(2):261-265.
[16]袁明霞,唐荣,周巧玲,等.冬虫夏草对糖尿病肾病大鼠肾组织HIF-1α及VEGF表达的影响[J].中南大学学报(医学版),2013,38(5):448-457.
[17]龚伟,黎磊石,陈丹,等.百令(冬虫夏草)对糖尿病大鼠转化生长因子β及其受体表达的影响[J].肾脏病与透析肾移植杂志,2006,15(4):329-339.
[18]余洪磊,周巧玲,黄仁发,等.冬虫夏草对大鼠肾缺血再灌注模型肾组织HIF-1α及NGAL表达的影响[J].中南大学学报(医学版),2012,37(1):57-66.
[19]张明辉,潘明明,倪海峰,等.冬虫夏草菌粉对5/6肾大部切除大鼠肾脏氧化应激及线粒体功能的影响[J].中国中西医结合杂志,2015,35(4):443-449.
[20]郭敏,杜跃亮,郭伟杰.百令对慢性肾衰竭大鼠模型肾纤维化治疗机制研究[J].中华实用诊断与治疗杂志,2014,28(3):229-231.
[21]朱辟疆,解冰,江利萍.肾炎康对大鼠系膜增生性肾炎白介素-6的影响[J].中国中西医结合肾病杂志,2005,6(11):19-21.
[22]刁金囡,吴燕,朱辟疆,等.新肾炎康颗粒对慢性肾炎患者尿IL-6、TGF-β1、MMP-9及TIMP-1的影响[J].中国中西医结合肾病杂志,2015,16(10):889-891.
[2]Zhang L,Wang F,Wang L,et al.Prevalence of chronic kidney disease in China:a cross-sectional survey[J].Lancet,2012,379(9818):815-822.
[3]林基伟,邹川,刘旭生.基于数据挖掘方法总结黄春林名老中医治疗慢性肾炎的用药经验[J].世界科学技术-中医药现代化,2015,17(2):382-388.
[4]李艳.国医大师李济仁治疗慢性肾炎蛋白尿经验[J].中华中医药杂志,2010,25(1):83-86.
[5]谢永祥,谢丽萍,蓝芳,等.广西地区慢性肾炎中医证型演变规律以及与尿蛋白、肾功能的相关性研究[J].现代中西医结合杂志,2014,23(16):1715-1717.
[6]刘丰喆,贺斐,何立群,等.慢性肾炎肾性血尿的中医研究近况[J].中国中西医结合肾病杂志,2015,16(5):453-454.
[7]刘宝厚,许筠.慢性肾小球肾炎的诊断、辨证分型及疗效评定(试行方案)[J].上海中医药杂志,2006,40(6):8-9.
[8]王立新,蔡佑青,莫业南,等.三芪颗粒治疗慢性肾炎的临床研究[J].广州中医药大学学报,2017,34(3):321-325.
[9]冯婷婷,郑启刚,王珍.余秉治治疗慢性肾小球肾炎经验[J].河南中医,2017,37(4):587-589.
[10]张玥.益肾化湿颗粒联合缬沙坦治疗慢性肾小球肾炎的临床研究[J].世界中医药,2017,12(1):68-70.
[11]李名波,孙智梅,任卓琴,等.氯沙坦钾片联合肾炎康复片治疗慢性肾小球肾炎蛋白尿的疗效观察[J].中国医院用药评价与分析,2017,17(1):75-76.
[12]陈成,王亿平.王亿平教授治疗慢性肾小球肾炎经验总结[J].陕西中医药大学学报,2017,40(1):27-29.
[13]胡贤达,黄雪,王彪,等.冬虫夏草抗肿瘤及免疫调节作用的研究进展[J].药物评价研究,2015,38(4):448-452.
[14]王林萍,余意,冯成强.冬虫夏草活性成分及药理作用研究进展[J].中国中医药信息杂志,2014,21(7):132-136.
[15]郝丽,潘梦舒,郑云,等.冬虫夏草及雷公藤多甙对糖尿病肾病大鼠足细胞影响的实验研究[J].中国中西医结合杂志,2012,32(2):261-265.
[16]袁明霞,唐荣,周巧玲,等.冬虫夏草对糖尿病肾病大鼠肾组织HIF-1α及VEGF表达的影响[J].中南大学学报(医学版),2013,38(5):448-457.
[17]龚伟,黎磊石,陈丹,等.百令(冬虫夏草)对糖尿病大鼠转化生长因子β及其受体表达的影响[J].肾脏病与透析肾移植杂志,2006,15(4):329-339.
[18]余洪磊,周巧玲,黄仁发,等.冬虫夏草对大鼠肾缺血再灌注模型肾组织HIF-1α及NGAL表达的影响[J].中南大学学报(医学版),2012,37(1):57-66.
[19]张明辉,潘明明,倪海峰,等.冬虫夏草菌粉对5/6肾大部切除大鼠肾脏氧化应激及线粒体功能的影响[J].中国中西医结合杂志,2015,35(4):443-449.
[20]郭敏,杜跃亮,郭伟杰.百令对慢性肾衰竭大鼠模型肾纤维化治疗机制研究[J].中华实用诊断与治疗杂志,2014,28(3):229-231.
[21]朱辟疆,解冰,江利萍.肾炎康对大鼠系膜增生性肾炎白介素-6的影响[J].中国中西医结合肾病杂志,2005,6(11):19-21.
[22]刁金囡,吴燕,朱辟疆,等.新肾炎康颗粒对慢性肾炎患者尿IL-6、TGF-β1、MMP-9及TIMP-1的影响[J].中国中西医结合肾病杂志,2015,16(10):889-891.